Your browser doesn't support javascript.
loading
Presence and activity of Fibrinogen like protein 2 in platelets.
Cherny, Izhack; Hasin, Pinhas; Philosoph, Lital Kalich; Shahal-Zimra, Yael; Gurion, Ronit; Rabizadeh, Esther.
Affiliation
  • Cherny I; Hemato-Oncology Laboratory, Felsenstein Medical Research Center, Petah Tikva, Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Hasin P; Hematology Laboratory, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
  • Philosoph LK; Hematology Laboratory, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
  • Shahal-Zimra Y; Hematology Laboratory, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
  • Gurion R; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Rabizadeh E; Hemato-Oncology Laboratory, Felsenstein Medical Research Center, Petah Tikva, Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
PLoS One ; 18(5): e0285735, 2023.
Article in En | MEDLINE | ID: mdl-37200306
ABSTRACT

BACKGROUND:

Fibrinogen-like protein 2 (FGL2) is a serine protease capable of converting prothrombin into thrombin (i.e., prothrombinase-like activity) while bypassing the classic coagulation cascade. It has been reported to be expressed by mononuclear blood cells and endothelial cells. There are multiple reports that FGL2 supports tumor development and metastasis. However, in the blood, the origin and functional significance of FGL2 has not been established.

OBJECTIVE:

To determine if FGL2, a malignancy related enzyme, is present in platelets.

METHODS:

Peripheral blood samples were collected in K2 EDTA tubes. Blood cells and platelets were separated and thoroughly washed to produce plasma-free samples. Procoagulant activity was measured in the cell lysates using a thrombin generation test or an adjusted prothrombin time (PT) test in plasma deficient of factor X. The findings were further supported by confocal microscopy, immunoprecipitation, flow cytometry, enzyme-linked immunosorbent assays and specific inhibition assays.

RESULTS:

FGL2 protein was readily detected in platelets. Also, despite being expressed by lymphocytes, FGL2 prothrombinase-like activity was solely detected in platelet samples, but not in white blood cell samples. Quiescent platelets were shown to contain the FGL2 protein in an active form. Upon activation, platelets secreted the active FGL2 into the milieu.

CONCLUSIONS:

Active FGL2 is found in platelets. This suggests another role for the involvement of platelets in malignancies.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thromboplastin / Thrombin Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2023 Type: Article Affiliation country: Israel

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thromboplastin / Thrombin Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2023 Type: Article Affiliation country: Israel